Biogen (BIIB) and Vanqua announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. Under the terms of the agreement, Biogen will obtain exclusive worldwide rights to Vanqua’s peripherally-directed C5aR1 program. Vanqua will receive a $70 million upfront payment and is eligible to receive up to $990 million in potential development, regulatory, commercial, and sales milestone payments, as well as tiered royalties on potential net sales. The upfront payment will be recorded by Biogen as an Acquired In-Process Research and Development expense in the fourth quarter of 2025. Biogen will lead all future development, manufacturing and commercialization efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen to present additional results from Phase 3 study of dapirolizumab pegol
- Biogen’s Hold Rating Justified by Limited Growth Prospects and Pipeline Uncertainty
- Biogen price target raised to $153 from $135 at Citi
- Biogen price target raised to $149 from $144 at Morgan Stanley
- Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies